Ebrahimi-Nik H, Michaux J, Corwin W, Keller G, Shcheglova T, Pak H
JCI Insight. 2019; 5.
PMID: 31219806
PMC: 6675551.
DOI: 10.1172/jci.insight.129152.
Srivastava P, Duan F
Cancer Immunol Immunother. 2013; 62(5):967-74.
PMID: 23604106
PMC: 3634982.
DOI: 10.1007/s00262-013-1422-x.
Avner P, Dove W, Dubois P, Gaillard J, Guenet J, Jacob F
Immunogenetics. 2011; 7(1):103-15.
PMID: 21302063
DOI: 10.1007/BF01843995.
Dalgleish A, Whelan M
Cancer Immunol Immunother. 2006; 55(8):1025-32.
PMID: 16506069
PMC: 11030604.
DOI: 10.1007/s00262-006-0128-8.
Prehn R
Theor Biol Med Model. 2006; 3:6.
PMID: 16457723
PMC: 1373614.
DOI: 10.1186/1742-4682-3-6.
On the nature of cancer and why anticancer vaccines don't work.
Prehn R
Cancer Cell Int. 2005; 5(1):25.
PMID: 16060965
PMC: 1185554.
DOI: 10.1186/1475-2867-5-25.
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.
Nishikawa H, Tanida K, Ikeda H, Sakakura M, Miyahara Y, Aota T
Proc Natl Acad Sci U S A. 2001; 98(25):14571-6.
PMID: 11724951
PMC: 64723.
DOI: 10.1073/pnas.251547298.
Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.
Ikeda H, Ohta N, Furukawa K, Miyazaki H, Wang L, Kuribayashi K
Proc Natl Acad Sci U S A. 1997; 94(12):6375-9.
PMID: 9177225
PMC: 21057.
DOI: 10.1073/pnas.94.12.6375.
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi Y, Jungbluth A, Richards E, Old L
Proc Natl Acad Sci U S A. 1996; 93(21):11798-801.
PMID: 8876217
PMC: 38138.
DOI: 10.1073/pnas.93.21.11798.
Heat shock protein 70-associated peptides elicit specific cancer immunity.
Udono H, Srivastava P
J Exp Med. 1993; 178(4):1391-6.
PMID: 8376942
PMC: 2191193.
DOI: 10.1084/jem.178.4.1391.
Heat shock proteins transfer peptides during antigen processing and CTL priming.
Srivastava P, Udono H, Blachere N, Li Z
Immunogenetics. 1994; 39(2):93-8.
PMID: 8276462
DOI: 10.1007/BF00188611.
Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.
Kitajima T, Iwashiro M, Kuribayashi K, Imamura S
Cancer Immunol Immunother. 1994; 38(6):372-8.
PMID: 8205558
PMC: 11038323.
DOI: 10.1007/BF01517206.
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E
J Exp Med. 1994; 180(5):1599-607.
PMID: 7964448
PMC: 2191716.
DOI: 10.1084/jem.180.5.1599.
Chromosome assignment of the tumor-specific antigen of a 3-methylcholanthrene-induced mouse sarcoma.
Pravtcheva D, DeLeo A, Ruddle F, Old L
J Exp Med. 1981; 154(3):964-77.
PMID: 7276830
PMC: 2186453.
DOI: 10.1084/jem.154.3.964.
Influence of immune status of host on immunogenicity of tumors induced with two doses of methylcholanthrene.
Lawler E, Prehn R
Cancer Immunol Immunother. 1982; 13(3):194-7.
PMID: 6762248
PMC: 11039173.
DOI: 10.1007/BF00205388.
Specificity of tumour associated transplantation antigens (TATA) of different clones from the same tumour.
Woodruff M, Ansell J, Hodson B, Micklem H
Br J Cancer. 1984; 49(1):5-10.
PMID: 6197985
PMC: 1976682.
DOI: 10.1038/bjc.1984.2.
Intratumor immunologic heterogeneity.
Miller F
Cancer Metastasis Rev. 1982; 1(4):319-34.
PMID: 6192904
DOI: 10.1007/BF00124215.
Tumour-associated transplantation antigens of neoplasms induced by a naturally occurring murine sarcoma virus (FBJ-MSV).
Jones D, Moore M
Br J Cancer. 1973; 27(6):415-26.
PMID: 4516007
PMC: 2008818.
DOI: 10.1038/bjc.1973.52.
A tumour-associated membrane antigen transiently expressed by normal cells during mitosis.
Bertini M, Forni G, Comoglio P
Clin Exp Immunol. 1974; 18(1):101-8.
PMID: 4468189
PMC: 1537971.
[Histochemical investigations of carcinogenesis in rat liver after time-limited application of diethylnitrosamine].
FRIEDRICH-FREKSA H, Papadopulu G, GOSSNER W
Z Krebsforsch. 1969; 72(3):240-53.
PMID: 4309585
